Jay Mukesh Chudasama

Jay Mukesh Chudasama

Auto-generated profile, based on publicly available information

Jay Mukesh Chudasama

Department of Pharmacy, Sumandeep Vidyapeeth Deemed to be University, Piparia, Waghodia, Vadodara, Gujarat, 391760, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2025 in Journal of Ayurveda and Integrative Medicine
Verified
Journal Article
Open access
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
JCJay Mukesh Chudasama
Jay Mukesh Chudasama
ASAshish Shah
Ashish Shah
CAChintan Aundhia
Chintan Aundhia
SKSunil Kardani
Sunil Kardani
Caryota urens, also known as Shivjata, has been documented in ancient Indian texts for its therapeutic benefits, addressing conditions from seminal weakness to gastric ulcers. This study aims to investigate its contemporary medicinal potential in treating breast cancer. The study focuses on exploring the therapeutic potential of Caryota urens fruit against breast cancer, specifically targeting cell cycle genes CDK1, CDC25A, and PLK1 through bioinformatics, network pharmacology, and in vitro validation. Using mass spectrometry and nuclear magnetic resonance (NMR), 60 key phytoconstituents from Caryota urens fruit were identified. Bioinformatics analysis, integrating Gene Cards and GEO databases, 15,474 breast cancer-associated genes focusing on the HR+/HER2-subtype were identified. Molecular docking and qPCR validated the interactions of key phytoconstituents, particularly Episesamin, with CDK1, CDC25A, and PLK1. In vitro studies were conducted on the MCF7 cell line, supplemented by ROC and survival analyses to evaluate diagnostic and therapeutic potential. The bioinformatics analysis identified CDK1, CDC25A, and PLK1 as pivotal genes regulating cell cycle progression and breast cancer tumorigenesis. Network pharmacology and in vitro studies indicated that phytoconstituents, especially Episesamin, downregulated these genes in breast cancer cells. Molecular docking and qPCR confirmed these interactions, and ROC and survival analyses underscored their diagnostic and therapeutic significance. This study suggests that Caryota urens fruit extract, particularly Episesamin, may inhibit breast cancer metastasis by downregulating CDK1, CDC25A, and PLK1, offering promising new strategies for targeting the cell cycle in breast cancer and emphasizing the value of integrating bioinformatics with experimental methods in cancer research.

1 January 2025 in Current Nanoscience
Verified
Journal Article
Closed access
PDF file
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
JCJay Mukesh Chudasama
Jay Mukesh Chudasama
CAChintan Aundhia
Chintan Aundhia
The pharmaceutical sciences are gradually shielding mankind from a plethora of deadly but as-of-yet-undiscovered ailments. Many diseases, some of which can be fatal, have their initial line of defence on the skin. A significant challenge for scientists is the development of appropriate pharmacological formulations for transdermal drug administration. Low side effect risk reduces first-pass impact, and good patient compliance makes transdermal distribution superior to oral delivery. This is why transdermal medication delivery is so important. Thanks to advancements in pharmaceutical delivery systems, the skin can now absorb medications more effectively. Researchers from different parts of the globe have investigated many different kinds of medications as possible transdermal delivery routes using electrospinning nanofibres. The skin can more easily absorb therapeutic compounds thanks to the nanofibres' ability to concentrate them. It is possible to load hydrophilic and lipophilic medications onto polymeric nanofibres. Another option is the transdermal distribution of biopolymer nanofibres. Over long periods of time, they control the release of medicinal substances. Nanofibres and nanoparticles allow for the controlled release of both hydrophobic and hydrophilic drugs. Transdermal and topical medication delivery using polymeric electrospinning nanofibres laden with nanoparticles and medicines is the subject of this research review. After that, we'll look at some practical instances of engineers using electrospinning fibres to control the release of drugs in reaction to environmental and internal factors. Afterwards, we will quickly go over the latest developments in tissue engineering, hard tissue engineering (which includes repairing musculoskeletal systems, bones, and cartilage), and cancer therapy that uses electrospin nanofiber scaffolds to control the distribution of drugs. Thanks to recent advancements in medicine and pharmaceuticals, nanofibres may soon be able to transport a wide variety of drugs, allowing for more targeted methods of cellular regeneration and topical medication delivery.

1 January 2026 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
CAChintan Aundhia
Chintan Aundhia
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
CTChitrali Talele
Chitrali Talele
RTRahul Trivedi
Rahul Trivedi
MKMamta Kumari
Mamta Kumari
JCJay Chudasama
Jay Chudasama
Alzheimer’s disease (AD) remains a major challenge in developing effective treatments due to its complex pathophysiology, including the accumulation of amyloid-beta plaques and tau tangles. Small interfering RNA (siRNA) technology offers promise for targeted gene silencing, but effective delivery to the central nervous system remains a significant obstacle. Viral vectors have emerged as potent delivery vehicles for transporting siRNA to neural tissues. This review explores the utilization of viral vectors for siRNA delivery in AD, focusing on delivery strategies and challenges. We discuss the design and optimization of viral vectors, targeting strategies, and safety considerations. Additionally, we examine recent advancements and prospects for enhancing viral vector-mediated siRNA delivery in AD.

31 July 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
JCJay Mukesh Chudasama
Jay Mukesh Chudasama
RMRajesh A. Maheshwari
Rajesh A. Maheshwari
DHDenish Hinsu
Denish Hinsu
ASAshish Prasenjit Shah
Ashish Prasenjit Shah
RBRamachandran Balaraman
Ramachandran Balaraman

12 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JCJay Mukesh Chudasama
Jay Mukesh Chudasama
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
Diabetic foot ulcers (DFUs) present a significant clinical challenge, characterized by chronic inflammation and impaired wound healing. This study employs Gene Ontology (GO) analysis to identify critical biological processes, molecular functions, cellular components, and pathways associated with DFUs, aiming to uncover novel therapeutic targets. The analysis reveals significant enrichment in biological processes such as Positive Regulation of miRNA Transcription and Regulation of miRNA Transcription, highlighting the crucial role of microRNAs, including hsa-miR-34a-5p, hsa-miR-155-5p, hsa-miR-17-5p, hsa-miR-29b-3p, hsa-miR-7-5p, hsa-miR-1-3p, and hsa-miR-23b-3p, in regulating wound healing and inflammation. Enriched molecular functions, such as DNA-binding Transcription Activator Activity and Protein Phosphatase Binding, suggest that targeting genes like TP53, GAPDH, AKT1, MYC, TNF, EGFR, STAT3, FN1, VEGFA, and JUN could modulate critical cellular processes and improve DFU management. The analysis also identifies key cellular components, including Vesicle and Platelet Alpha Granule Lumen, as crucial for cellular transport and signaling, suggesting that interventions targeting these components could enhance wound repair. Furthermore, enriched pathways such as Proteoglycans in Cancer and Human Cytomegalovirus Infection indicate potential mechanisms and viral influences relevant to DFUs. These findings provide a comprehensive framework for developing targeted therapies that address the multifaceted pathology of DFUs, offering promising avenues for improving patient outcomes and advancing wound healing strategies.

5 May 2026 in Molecular Diversity
Verified
Journal Article
Closed access
Ghanshyam ParmarGhanshyam Parmar
Ghanshyam Parmar
JCJay Mukesh Chudasama
Jay Mukesh Chudasama
ASAshish Prasenjit Shah
Ashish Prasenjit Shah
CAChintan Aundhia
Chintan Aundhia
APAshish Patel
Ashish Patel
RBRavi Bansal
Ravi Bansal